Literature DB >> 8992320

Purification and characterization of three larval excretory-secretory proteins of Dirofilaria immitis.

G R Frank1, R B Grieve.   

Abstract

Two proteins were previously described in the excretory-secretory products (ES) collected from Dirofilaria immitis during the molt from the third stage to the fourth stage in vitro. The two proteins were purified using cation exchange and reverse phase HPLC. During the purification of these two proteins, a third protein was identified that co-migrated with one of the others during previous gel analysis. All three had molecular masses of 20-23 kDa as determined by Tris-glycine SDS-PAGE and have been designated 20, 22L and 22U kDa proteins. The three proteins were digested with trypsin. Amino acid sequences were subsequently determined for four peptides and the N-terminus of the 20 kDa protein, five peptides of the 22L kDa protein and three peptides of the 22U kDa protein. The 20 and 22L kDa proteins were quite similar based on sequence and purification characteristics. The 22U kDa protein, but not the 20 and 22L kDa proteins, was also identified in adult worms using tryptic mapping and amino acid sequencing techniques. Immunoblot analysis demonstrated that the 20 and 22L kDa proteins were specifically recognized by sera from dogs immune to infection by D. immitis but not by sera from infected non-immune dogs. The 22U kDa protein was weakly recognized by the same immune sera but not by the infected non-immune dog sera. Since the 20 and 22L kDa proteins appear to be larval specific, associated in time with the molt from L3 to L4 and are specifically recognized by immune dog sera, they are good vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8992320     DOI: 10.1016/0166-6851(95)02533-2

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  7 in total

Review 1.  A comprehensive, model-based review of vaccine and repeat infection trials for filariasis.

Authors:  C Paul Morris; Holly Evans; Sasha E Larsen; Edward Mitre
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

2.  The abundant larval transcript-1 and -2 genes of Brugia malayi encode stage-specific candidate vaccine antigens for filariasis.

Authors:  W F Gregory; A K Atmadja; J E Allen; R M Maizels
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  Development of a recombinant antigen vaccine against infection with the filarial worm Onchocerca volvulus.

Authors:  D Abraham; O Leon; S Leon; S Lustigman
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

4.  Analysis of genes expressed at the infective larval stage validates utility of Litomosoides sigmodontis as a murine model for filarial vaccine development.

Authors:  J E Allen; J Daub; D Guiliano; A McDonnell; M Lizotte-Waniewski; D W Taylor; M Blaxter
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

5.  Immune response studies with Wuchereria bancrofti vespid allergen homologue (WbVAH) in human lymphatic filariasis.

Authors:  Setty Balakrishnan Anand; Munirathinam Gnanasekar; Mani Thangadurai; Prince R Prabhu; Perumal Kaliraj; Kalyanasundaram Ramaswamy
Journal:  Parasitol Res       Date:  2007-06-09       Impact factor: 2.289

Review 6.  Examining the role of macrolides and host immunity in combatting filarial parasites.

Authors:  Doug S Carithers
Journal:  Parasit Vectors       Date:  2017-04-14       Impact factor: 3.876

Review 7.  Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With Onchocerca ochengi.

Authors:  Bin Zhan; Maria Elena Bottazzi; Peter J Hotez; Sara Lustigman
Journal:  Front Cell Infect Microbiol       Date:  2022-04-04       Impact factor: 6.073

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.